ES2834617T3 - Composiciones y métodos de uso para la determinación de HE4a - Google Patents

Composiciones y métodos de uso para la determinación de HE4a Download PDF

Info

Publication number
ES2834617T3
ES2834617T3 ES11858800T ES11858800T ES2834617T3 ES 2834617 T3 ES2834617 T3 ES 2834617T3 ES 11858800 T ES11858800 T ES 11858800T ES 11858800 T ES11858800 T ES 11858800T ES 2834617 T3 ES2834617 T3 ES 2834617T3
Authority
ES
Spain
Prior art keywords
he4a
antibody
polypeptide
antigen
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11858800T
Other languages
English (en)
Spanish (es)
Inventor
Ingegerd Hellstrom
Karl-Erik Hellstrom
John Raycroft
Christian Fermer
Eva Roijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Diagnostics Inc
Original Assignee
Fujirebio Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Diagnostics Inc filed Critical Fujirebio Diagnostics Inc
Application granted granted Critical
Publication of ES2834617T3 publication Critical patent/ES2834617T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES11858800T 2011-02-17 2011-02-17 Composiciones y métodos de uso para la determinación de HE4a Active ES2834617T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/025321 WO2012112160A1 (en) 2011-02-17 2011-02-17 Compositions and methods of use for determination of he4a

Publications (1)

Publication Number Publication Date
ES2834617T3 true ES2834617T3 (es) 2021-06-18

Family

ID=46672864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11858800T Active ES2834617T3 (es) 2011-02-17 2011-02-17 Composiciones y métodos de uso para la determinación de HE4a

Country Status (12)

Country Link
US (3) US9822169B2 (enExample)
EP (1) EP2675911B1 (enExample)
JP (1) JP5887364B2 (enExample)
KR (3) KR101854110B1 (enExample)
CN (1) CN103492582B (enExample)
AU (1) AU2011359350B2 (enExample)
BR (1) BR112013021056B1 (enExample)
CA (1) CA2827618C (enExample)
ES (1) ES2834617T3 (enExample)
IL (1) IL227924B (enExample)
RU (1) RU2650778C2 (enExample)
WO (1) WO2012112160A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
ES2834617T3 (es) * 2011-02-17 2021-06-18 Fujirebio Diagnostics Inc Composiciones y métodos de uso para la determinación de HE4a
CN106432492A (zh) * 2015-08-07 2017-02-22 广州瑞博奥生物技术有限公司 针对肿瘤标志物建立的抗体组合及其elisa方法
JP6613490B2 (ja) * 2016-02-19 2019-12-04 国立大学法人 宮崎大学 腺癌の検出方法
USD922352S1 (en) 2019-01-04 2021-06-15 Dolby Laboratories Licensing Corporation Speaker
JP7539369B2 (ja) * 2019-04-02 2024-08-23 大塚製薬株式会社 病態情報生成方法、病態情報生成システム、ｈｅ４糖鎖分析キット及びｈｅ４
CN111620939B (zh) * 2019-10-25 2021-01-01 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58
USD940793S1 (en) * 2019-11-22 2022-01-11 Microsoft Corporation Electronic device
JPWO2021261483A1 (enExample) * 2020-06-23 2021-12-30
US20240353411A1 (en) * 2022-04-08 2024-10-24 Ajou University Industry-Academic Cooperation Foundation He4 detecting peptide and use thereof
CN117487018B (zh) * 2023-09-27 2024-05-17 武汉爱博泰克生物科技有限公司 抗人附睾分泌蛋白4的兔单克隆抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
PL1620082T3 (pl) * 2003-05-05 2010-10-29 Probiodrug Ag Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
JP4744109B2 (ja) 2004-07-20 2011-08-10 トヨタ自動車株式会社 半導体装置とその製造方法
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
ATE408828T1 (de) * 2005-02-16 2008-10-15 Dana Farber Cancer Inst Inc Verfahren zur erkennung eines ovarialkarzinoms
US20070286865A1 (en) 2006-01-04 2007-12-13 Richard Moore Use of HE4 and other biochemical markers for assessment of ovarian cancers
JP2009524438A (ja) * 2006-01-27 2009-07-02 トライパス イメージング インコーポレイテッド 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物
EP2121761A1 (en) * 2007-03-09 2009-11-25 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
US8455189B2 (en) 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
MX2013002268A (es) * 2010-08-26 2014-02-03 Univ Washington Ct Commerciali Metodos para detectar anticuerpos anti-he4 y metodos de diagnosis y/o de prognosis de condiciones asociadas con celulas que expresan he4.
ES2834617T3 (es) * 2011-02-17 2021-06-18 Fujirebio Diagnostics Inc Composiciones y métodos de uso para la determinación de HE4a
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease

Also Published As

Publication number Publication date
US20180057575A1 (en) 2018-03-01
AU2011359350B2 (en) 2016-07-14
US20200325215A1 (en) 2020-10-15
CN103492582A (zh) 2014-01-01
JP5887364B2 (ja) 2016-03-16
RU2013142334A (ru) 2015-03-27
AU2011359350A2 (en) 2014-05-01
US9822169B2 (en) 2017-11-21
WO2012112160A1 (en) 2012-08-23
AU2011359350A1 (en) 2013-09-12
EP2675911A1 (en) 2013-12-25
US20150353629A1 (en) 2015-12-10
KR20200013118A (ko) 2020-02-05
CA2827618C (en) 2019-08-06
JP2014507153A (ja) 2014-03-27
CA2827618A1 (en) 2012-08-23
IL227924A0 (en) 2013-09-30
KR20180014239A (ko) 2018-02-07
KR101854110B1 (ko) 2018-05-04
KR102074141B1 (ko) 2020-02-07
BR112013021056A2 (pt) 2016-08-09
IL227924B (en) 2019-01-31
KR20140025348A (ko) 2014-03-04
CN103492582B (zh) 2016-06-22
EP2675911A4 (en) 2015-04-01
RU2650778C2 (ru) 2018-04-17
EP2675911B1 (en) 2020-11-04
BR112013021056B1 (pt) 2022-03-29

Similar Documents

Publication Publication Date Title
US20200325215A1 (en) COMPOSITIONS AND METHODS OF USE FOR DETERMINATION OF HE4a
ES2269105T3 (es) Metodos y composiciones para el diagnostico de carcinomas.
JP5188443B2 (ja) 癌腫の診断
US6770445B1 (en) Methods and compositions for diagnosing carcinomas
KR101750411B1 (ko) 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
KR20120095301A (ko) 항-사이토케라틴 8/18 복합체 자가면역항체를 포함하는 암 진단 마커 및 이의 항원을 포함하는 암 진단용 조성물
US7745159B2 (en) Methods and compositions for diagnosing carcinomas
HK1191056B (en) Compositions and methods of use for determination of he4a
JP2012018119A (ja) 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法
US20110104675A1 (en) Methods and Compositions for Diagnosing Carcinomas
CN117447598A (zh) 一种磷酸化人体pd-l1蛋白特异性抗体及其制备方法和应用